Today, a Director at Orthofix (NASDAQ: OFIX), Ronald Matricaria, bought shares of OFIX for $519.7K.
Following Ronald Matricaria’s last OFIX Buy transaction on June 02, 2015, the stock climbed by 19.2%. Following this transaction Ronald Matricaria’s holding in the company was increased by 10.92% to a total of $5.32 million.
See today’s analyst top recommended stocks >>
Based on Orthofix’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $109 million and quarterly net profit of $5.23 million. In comparison, last year the company earned revenue of $103 million and had a GAAP net loss of $2.65 million. OFIX’s market cap is $964.3M and the company has a P/E ratio of 68.04. Currently, Orthofix has an average volume of 174.7K.
Starting in May 2017, OFIX received 19 Buy ratings in a row. Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $65.67, reflecting a -20.2% downside. Six different firms, including BTIG and Canaccord Genuity, currently also have a Buy rating on the stock.
Ronald Matricaria’s trades have generated a 6.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Orthofix International NV engages in the research, development, and market of orthopedic solutions. It operates through the following business segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation.